Results 131 to 140 of about 2,525 (153)
Some of the next articles are maybe not open access.
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam
Antimicrobial Agents and Chemotherapy, 2022Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel β-lactam/β-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non- Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseudomonas aeruginosa .
J. Nicholas O’Donnell +1 more
openaire +2 more sources
Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales
Clinical Microbiology and Infection, 2023The treatment options for infections caused by carbapenem-resistant Enterobacterales are scarce and the development of new antibiotics is an urgent necessity. Imipenem/relebactam (IPR) has been recently introduced for treating severe infections related to multidrug-resistant bacteria.
Maxime, Bouvier +4 more
openaire +2 more sources
Chemical Communications, 2022
The first catalytic asymmetric total synthesis of marketed DBO β-lactamase inhibitors avibactam and relebactam has been achievedviaa Rh-catalysed asymmetric hydrogenation along with multiple flow procedures.
Zhi Yang +5 more
openaire +2 more sources
The first catalytic asymmetric total synthesis of marketed DBO β-lactamase inhibitors avibactam and relebactam has been achievedviaa Rh-catalysed asymmetric hydrogenation along with multiple flow procedures.
Zhi Yang +5 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 2022
Abstract Background Imipenem and relebactam are predominantly excreted via glomerular filtration. Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations are of concern.
Andrew J, Fratoni +3 more
openaire +2 more sources
Abstract Background Imipenem and relebactam are predominantly excreted via glomerular filtration. Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations are of concern.
Andrew J, Fratoni +3 more
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2020
The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens.
S.G. Kuiper +3 more
openaire +2 more sources
The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens.
S.G. Kuiper +3 more
openaire +2 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy
Clinical Pharmacokinetics, 2020On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work ...
openaire +2 more sources
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa
Diagnostic Microbiology and Infectious DiseaseImipenem-relebactam (IPR) has been reported to exhibit a good activity against non-metallo-ß-lactamase carbapenem-resistant Pseudomonas aeruginosa (CRPA), and the rapid detection of susceptibility/resistance to this new therapeutic alternative may be crucial.
Maxime Bouvier +3 more
openaire +2 more sources
Drugs, 2017
Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor.
George G, Zhanel +13 more
openaire +2 more sources
Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor.
George G, Zhanel +13 more
openaire +2 more sources